Trial Profile
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2022
Price :
$35
*
At a glance
- Drugs Valbenazine (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Adverse reactions
- Acronyms T-Force GOLD Plus
- Sponsors Neurocrine Biosciences
- 01 Apr 2019 Status changed from recruiting to discontinued.
- 15 Nov 2018 New trial record